Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Total Liabilities
Everything the company owes to creditors and other parties.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 7.5% from a year ago
Total liabilities stood at $33.06M at the end of Q3 FY2026, up 7.5% from a year earlier and up 30.2% from the prior quarter. Over 3 fiscal years it compounded at -18.6% a year.
Context
- Total liabilities amounted to 4.2% of total assets at the end of Q3 FY2026, down 4.3 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +7.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.39M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- -42.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.39M | -5.1% |
| FY2024 | 2024-12-31 | 28.87M | -65.6% |
| FY2023 | 2023-12-31 | 84.02M | +65.2% |
| FY2022 | 2022-12-31 | 50.85M | -80.2% |
| FY2021 | 2021-12-31 | 256.78M | — |
Total Liabilities vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +7.5% is the 3rd highest of 10, against a peer median of -1.1%.
- Total liabilities amounts to 4.2% of total assets for AMLX, versus a peer median of 27.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.52B USD | +4.3% | +15.7% | 86.5% | |
| Jun 2026 | $322.78M USD | +131.9% | -32.0% | 27.9% | |
| Mar 2026 | CHF 105.89M CHF | -8.9% | +86.2% | 77.1% | |
| Sep 2026 | $52.5M USD | -0.7% | +15.3% | 4.0% | |
| Mar 2026 | $46.21M USD | -1.1% | +117.0% | 31.5% | |
| Mar 2026 | $40.47M USD | +33.6% | -4.7% | 186.8% | |
| Mar 2026 | $37.28M USD | -35.3% | -30.2% | 10.7% | |
| Sep 2026 | $33.06M USD | +7.5% | -18.6% | 4.2% | |
| Jun 2026 | $7.29M USD | -26.3% | -11.5% | 12.9% | |
| Dec 2025 | $6.37M USD | -51.5% | -4.3% | 4.8% | |
| Peer median (excluding AMLX) | — | -1.1% | -4.3% | 27.9% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.19M | 62.53M | 170.2M | 77.39M | 226.65M |
| Short-term Investments | 45.93M | 284.42M | 201.16M | 99.11M | 90.33M |
| Net Receivables | 0 | 15.31M | 40.05M | 447K | 88K |
| Inventory | 0 | 9.77M | 38.32M | 0 | 0 |
| Other Current Assets | 3.44M | 10.11M | 14.93M | 12.48M | 6.6M |
| Total Current Assets | 104.95M | 382.13M | 464.67M | 189.43M | 323.67M |
| Property, Plant & Equipment (Net) | 474K | 8.14M | 6.41M | 2.73M | 5.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 189K | 1.19M | 46.38M | 1.47M | 3.48M |
| Total Non-current Assets | 663K | 9.32M | 52.79M | 4.2M | 8.97M |
| Total Assets | 105.61M | 391.45M | 517.45M | 193.63M | 332.65M |
| Account Payables | 4.37M | 6.26M | 22.06M | 2.94M | 3.52M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.28M | 15.23M | 40.93M | 9.99M | 10.06M |
| Total Current Liabilities | 17.4M | 46.61M | 82.04M | 28.41M | 22.69M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.7M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.39M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 239.39M | 4.24M | 1.98M | 463K | 4.7M |
| Total Liabilities | 256.78M | 50.85M | 84.02M | 28.87M | 27.39M |
| Common Stock | 1K | 7K | 7K | 7K | 11K |
| Retained Earnings | (155.85M) | (354.22M) | (304.95M) | (606.69M) | (751.43M) |
| Accumulated OCI | 9K | (86K) | 197K | (92K) | 404K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (151.17M) | 340.61M | 433.43M | 164.77M | 305.26M |
| Total Debt | 0 | 6.28M | 4.24M | 1.98M | 5.96M |
| Net Debt | (50.19M) | (56.25M) | (165.96M) | (75.41M) | (220.69M) |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.